MASH 2021 Spring Symposium
Check back soon for Registration details
Description of our 2020 Fall Business Meeting:
SATURDAY, NOVEMBER 14TH, 10am EST
Mirna Lechpammer, MD, Ph.D.
Senior Pathologist, Neuropathologist and Associate Medical Director
"Comprehensive Genomic Profiling: An Overview and Best Practices for Improving Assay Success"
Mirna Lechpammer, MD, Ph.D. is a Senior Pathologist, Neuropathologist and an Associate Medical Director at the Pathology and Diagnostic Medicine, Foundation Medicine, Inc. Cambridge, MA; and currently also holds a position of an Adjunct Associate Professor at the New York University Langone Medical Center. Dr. Lechpammer joined Foundation Medicine in March 2020 from positions of a tenured Associate Professor in the Department of Pathology and Laboratory Medicine at the University of California Davis Medical School and the Director of CLIA certified Molecular Laboratory at the MIND Institute in Sacramento, CA. Her Laboratory focused on investigation of hypoxia-driven pathogenic mechanisms and alterations in metabolic functions in gliomas, as potential new diagnostic markers and therapeutic targets.
Dr. Lechpammer has obtained MD and Ph.D. degrees from the University of Zagreb Medical School in Zagreb, Croatia. Her anatomic pathology training included Anatomic Pathology residency at the Rhode Island Hospital and Warren Alpert Medical School of Brown University in Providence, RI and Neuropathology fellowship at Brigham and Women’s Hospital and Harvard Medical School in Boston, MA. Dr. Lechpammer has authored over eighty peer-reviewed manuscripts, congress abstracts and book chapters. She was awarded twice (2009 and 2017) for her research contributions with the Moore Award for the best clinico-pathologic paper in Neuropathology by the American Association of Neuropathologists (AANP). Dr. Lechpammer is presently completing work as one of three principal authors and editors of the major textbook “Perinatal Neuropathology” to be published by the Cambridge University Press, London, UK in early 2021.